Last reviewed · How we verify

Pfizer-COVID-19 Vaccine — Competitive Intelligence Brief

Pfizer-COVID-19 Vaccine (Pfizer-COVID-19 Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Immunology / Infectious Disease.

marketed mRNA vaccine SARS-CoV-2 spike protein (S protein) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Pfizer-COVID-19 Vaccine (Pfizer-COVID-19 Vaccine) — National Heart, Lung, and Blood Institute (NHLBI). This mRNA vaccine instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response that protects against COVID-19 infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pfizer-COVID-19 Vaccine TARGET Pfizer-COVID-19 Vaccine National Heart, Lung, and Blood Institute (NHLBI) marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)
Comirnaty Original/Omicron BA.4-5 Comirnaty Original/Omicron BA.4-5 Jules Bordet Institute marketed mRNA vaccine SARS-CoV-2 spike protein (original strain and Omicron BA.4-5 variants)
Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose variant-adapted-bnt162b2-omicron-xbb-1-5-10-microgram-dose Pfizer marketed mRNA vaccine SARS-CoV-2 spike protein
The Pfizer mRNA-based BNT162b2 vaccine The Pfizer mRNA-based BNT162b2 vaccine dafna yahav marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)
mRNA-1273 Variant-containing Formulation mRNA-1273 Variant-containing Formulation ModernaTX, Inc. marketed mRNA vaccine SARS-CoV-2 spike protein (variant-specific)
Spikevax bivalent Original/Omicron BA.1 Spikevax bivalent Original/Omicron BA.1 Jules Bordet Institute marketed mRNA vaccine SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant)
BNT162b2 BA.4/5 bivalent bnt162b2-ba-4-5-bivalent Pfizer marketed mRNA vaccine SARS-CoV-2 virus

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

  1. Pfizer · 12 drugs in this class
  2. ModernaTX, Inc. · 11 drugs in this class
  3. BioNTech SE · 5 drugs in this class
  4. Jules Bordet Institute · 5 drugs in this class
  5. Tan Tock Seng Hospital · 2 drugs in this class
  6. Clover Biopharmaceuticals AUS Pty · 1 drug in this class
  7. CanSino Biologics Inc. · 1 drug in this class
  8. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  9. CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
  10. Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pfizer-COVID-19 Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/pfizer-covid-19-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: